BR112017015661A2 - anticorpo anti-alk2 - Google Patents

anticorpo anti-alk2

Info

Publication number
BR112017015661A2
BR112017015661A2 BR112017015661-0A BR112017015661A BR112017015661A2 BR 112017015661 A2 BR112017015661 A2 BR 112017015661A2 BR 112017015661 A BR112017015661 A BR 112017015661A BR 112017015661 A2 BR112017015661 A2 BR 112017015661A2
Authority
BR
Brazil
Prior art keywords
antibody
alk2
alk2 antibody
dipg
anemia
Prior art date
Application number
BR112017015661-0A
Other languages
English (en)
Japanese (ja)
Inventor
Katagiri Takenobu
Osawa Kenji
Tsukamoto Sho
Tsuji Shinnosuke
Kawaguchi Yoshirou
Nakamura Kensuke
Original Assignee
Saitama Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saitama Medical University filed Critical Saitama Medical University
Publication of BR112017015661A2 publication Critical patent/BR112017015661A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

a presente invenção refere-se a um anticorpo que se liga especificamente a uma proteína alk2 e tem uma atividade de inibição da transdução de sinal de bmp mediada por alk2; um método para produzir o anticorpo; e uma composição farmacêutica compreendendo o anticorpo, para tratar e/ou prevenir a ossificação ectópica e/ou displasia óssea, anemia ou glioma pontino intrínseco difuso (dipg).
BR112017015661-0A 2015-01-30 2016-01-29 anticorpo anti-alk2 BR112017015661A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015-017882 2015-01-30
JP2015017882 2015-01-30
PCT/JP2016/052602 WO2016121908A1 (ja) 2015-01-30 2016-01-29 抗ａｌｋ２抗体

Publications (1)

Publication Number Publication Date
BR112017015661A2 true BR112017015661A2 (pt) 2018-03-20

Family

ID=56543512

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017015661-0A BR112017015661A2 (pt) 2015-01-30 2016-01-29 anticorpo anti-alk2

Country Status (9)

Country Link
US (3) US10428148B2 (pt)
EP (1) EP3252074A4 (pt)
JP (2) JP6763783B2 (pt)
KR (1) KR20170105558A (pt)
CN (2) CN107207604B (pt)
BR (1) BR112017015661A2 (pt)
CA (1) CA2975376A1 (pt)
TW (2) TWI774028B (pt)
WO (1) WO2016121908A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016121908A1 (ja) * 2015-01-30 2016-08-04 学校法人埼玉医科大学 抗ａｌｋ２抗体
GB201510758D0 (en) * 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
US20190254264A1 (en) * 2016-10-31 2019-08-22 National University Corporation Tottori University Human antibody-producing non-human animal and method for preparing human antibodies using same
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
CA3048376A1 (en) 2016-12-27 2018-07-05 Riken Bmp-signal-inhibiting compound
US11859006B2 (en) 2018-03-05 2024-01-02 Saitama Medical University Method of treating ectopic ossification or diffuse intrinsic pontine glioma in a subject by administering an anti-ALK2 antibody
CN109438572A (zh) * 2018-10-15 2019-03-08 上海药明生物技术有限公司 连续应用亲和层析和陶瓷羟基磷灰石层析分离抗体药物的方法
EP3870613A4 (en) * 2018-10-23 2022-08-03 Keros Therapeutics, Inc. ALK2 ANTIBODIES AND METHODS OF USE THEREOF
WO2020118011A1 (en) * 2018-12-06 2020-06-11 Alexion Pharmaceuticals, Inc. Anti-alk2 antibodies and uses thereof
JP2021017416A (ja) * 2019-07-19 2021-02-15 国立大学法人京都大学 Ａｌｋ２の変異を有する疾患の治療または予防用医薬組成物
JPWO2021020282A1 (pt) 2019-07-26 2021-02-04
WO2021163170A1 (en) * 2020-02-11 2021-08-19 Regeneron Pharmaceuticals, Inc. Anti-acvr1 antibodies and uses thereof
IL295980A (en) * 2020-02-28 2022-10-01 Brigham & Womens Hospital Inc Selective modulation of transforming growth factor beta superfamily signaling using multispecific antibodies
EP4047955A1 (en) 2021-02-17 2022-08-24 Oticon A/s A hearing aid comprising a feedback control system

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007123896A2 (en) 2006-04-18 2007-11-01 The Trustees Of The University Of Pennsylvania Mutated acvr1 for diagnosis and treatment of fibrodyplasia ossificans progressiva (fop)
US20110182904A1 (en) 2006-09-05 2011-07-28 Deborah Zimmerman Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
IE20090514A1 (en) 2009-07-06 2011-02-16 Opsona Therapeutics Ltd Humanised antibodies and uses therof
EP2332995A1 (en) 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
WO2011112671A2 (en) * 2010-03-09 2011-09-15 President And Fellows Of Harvard College Conversion of vascular endothelial cells into multipotent stem-like cells
TR201802772T4 (tr) * 2010-11-17 2018-03-21 Chugai Pharmaceutical Co Ltd Kan pıhtılaşma faktörü VIII in işlevi için alternatif işleve sahip multi-spesifik antijen bağlayıcı molekül.
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
JPWO2014051109A1 (ja) * 2012-09-28 2016-08-25 協和発酵キリン株式会社 抗ヒトｂｍｐ９抗体および該抗体を有効成分とする異所性骨化疾患の治療剤
WO2014078306A1 (en) 2012-11-13 2014-05-22 Regeneron Pharmaceuticals, Inc. Anti-prokineticin receptor (prokr) antibodies and uses thereof
WO2016121908A1 (ja) * 2015-01-30 2016-08-04 学校法人埼玉医科大学 抗ａｌｋ２抗体
CN107488625B (zh) 2017-08-31 2018-12-21 广州蕊特生物科技有限公司 一种胎牛血清替代物及其制备方法和应用
US11859006B2 (en) 2018-03-05 2024-01-02 Saitama Medical University Method of treating ectopic ossification or diffuse intrinsic pontine glioma in a subject by administering an anti-ALK2 antibody

Also Published As

Publication number Publication date
JP7101732B2 (ja) 2022-07-15
JP2021006535A (ja) 2021-01-21
US20180118835A1 (en) 2018-05-03
TWI703156B (zh) 2020-09-01
CA2975376A1 (en) 2016-08-04
CN107207604A (zh) 2017-09-26
EP3252074A4 (en) 2018-07-11
CN113980131A (zh) 2022-01-28
TW202110894A (zh) 2021-03-16
US10428148B2 (en) 2019-10-01
JP6763783B2 (ja) 2020-09-30
US11312776B2 (en) 2022-04-26
JPWO2016121908A1 (ja) 2017-11-09
CN107207604B (zh) 2021-10-26
US20220041738A1 (en) 2022-02-10
US11447554B2 (en) 2022-09-20
WO2016121908A1 (ja) 2016-08-04
EP3252074A1 (en) 2017-12-06
TW201636368A (zh) 2016-10-16
TWI774028B (zh) 2022-08-11
US20200002427A1 (en) 2020-01-02
KR20170105558A (ko) 2017-09-19

Similar Documents

Publication Publication Date Title
BR112017015661A2 (pt) anticorpo anti-alk2
BR112019006642A2 (pt) antagonistas multiméricos de e-selectina altamente potentes
CY1121359T1 (el) Ενωσεις ετεροαρυλιου για αναστολη κινασης
CL2019000325A1 (es) Composicion farmaceutica que comprende un compuesto derivado de piridona policiclico sustituido o su sal, que tiene actividad inhibidora de la endonucleasa dependiente de cap; cristal; y composicion farmaceutica que comprende dicho cristal.
BR112018070919A2 (pt) anticorpos anti-tim-3 e composições
CL2019000266A1 (es) Composición de cannabis.
BR112018016697A2 (pt) anticorpo revestido, quimérico ou humanizado, composição farmacêutica, e, método de tratamento.
BR112015029969A2 (pt) tratamento de câncer usando moduladores de isoformas quinase pi3
BR112017016636A2 (pt) formulação líquida estável para anticorpos monoclonais
BR112016022910A2 (pt) anticorpos contra her2 biespecíficos
BR112017014341A2 (pt) método e sistema para tratamento, estabilização, ou redução da gravidade ou progressão de uma doença de fígado gorduroso não alcoólica, e, composição.
CO6551721A2 (es) Moduladores de cinasa novedosos
BR112017008714A2 (pt) inibidores de bromodomínio
EA201592143A1 (ru) Новые бициклические ингибиторы бромодомена
CL2016000221A1 (es) Anticuerpos anti-fgfr2iiib afucosilados.
BR112018011131A2 (pt) terapia de combinação baseada em inibidores de sinal de pd-1
CR20110103A (es) Heteroarilos sustituidos
PH12018500653A1 (en) Salts and solid forms of monobactam antibiotic
BR112016027881A2 (pt) antagonistas de pdl-1 e pd-1 para o tratamento de cânceres negativos para o hpv
BR112016025056A2 (pt) uso de pelo menos um polipeptídeo, anticorpo biespecífico, anticorpo biespecífico isolado, anticorpo her3/her2 biespecífico, célula hospedeira, método de produção do anticorpo biespecífico her3/her2, imunoconjugado e formulação farmacêutica
BR112019023990A2 (pt) Bis-octa-hidrofenantreno carboxamidas e conjugados de proteína das mesmas
BR112017010311A2 (pt) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
BR112018072211A2 (pt) anticorpos anti tl1a e utilizações dos mesmos
BR112017014793A2 (pt) regime de dosagem para antagonistas de madcam
PH12015501360A1 (en) Bmp-6 antibodies

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]